This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Yasmin Khaliq, PharmD; Kenneth C. Lamp, PharmD
Detroit, Mich

Arch Intern Med. 1993;153(6):782-783.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Martin and colleagues¹ recently published results of a retrospective chart review evaluating the effectiveness of three regimens for the prophylaxis of Pneumocystis carinii pneumonia (PCP). They reported an incidence of relapse for trimethoprimsulfamethoxazole (double-strength tablet orally twice a day, given 3 days per week), dapsone (50 mg every day), and aerosolized pentamidine (300 mg once every month) of 0%, 6.5%, and 13.6%, respectively. Trimethoprim-sulfamethoxazole was the primary prophylactic regimen. The authors concluded that trimethoprim-sulfamethoxazole was the most effective regimen for primary and secondary prophylaxis of PCP.

We have several concerns regarding the validity of the study design and conclusions. One potential complicating factor in this study is the nonrandomized nature of patient selection for each prophylactic regimen. Were there any specific exclusion criteria, such as asthma (steroid therapy), recent prior PCP treatment, or expected survival of less than 1 week?^2,3 No mention of comparability among the three groups . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?